TW200732339A - Nitrogen-containing bicyclic heteroaryl compounds and methods of use - Google Patents
Nitrogen-containing bicyclic heteroaryl compounds and methods of useInfo
- Publication number
- TW200732339A TW200732339A TW095148534A TW95148534A TW200732339A TW 200732339 A TW200732339 A TW 200732339A TW 095148534 A TW095148534 A TW 095148534A TW 95148534 A TW95148534 A TW 95148534A TW 200732339 A TW200732339 A TW 200732339A
- Authority
- TW
- Taiwan
- Prior art keywords
- methods
- nitrogen
- compounds
- bicyclic heteroaryl
- heteroaryl compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000009929 raf Kinases Human genes 0.000 abstract 3
- 108010077182 raf Kinases Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000029499 cancer-related condition Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75370505P | 2005-12-23 | 2005-12-23 | |
US11/643,261 US7989461B2 (en) | 2005-12-23 | 2006-12-20 | Substituted quinazolinamine compounds for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200732339A true TW200732339A (en) | 2007-09-01 |
Family
ID=38016465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095148534A TW200732339A (en) | 2005-12-23 | 2006-12-22 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use |
Country Status (9)
Country | Link |
---|---|
US (2) | US7989461B2 (zh) |
EP (2) | EP1976836B9 (zh) |
AR (1) | AR057997A1 (zh) |
AU (1) | AU2006330888B2 (zh) |
CA (2) | CA2634769C (zh) |
ES (1) | ES2392673T3 (zh) |
PE (1) | PE20071328A1 (zh) |
TW (1) | TW200732339A (zh) |
WO (1) | WO2007076092A2 (zh) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06012613A (es) * | 2004-05-07 | 2007-01-31 | Amgen Inc | Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer. |
DE102005038947A1 (de) * | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
EP1899332A1 (en) | 2005-06-24 | 2008-03-19 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c. |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
US7560551B2 (en) * | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
US7868177B2 (en) * | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
US8338435B2 (en) | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
TW200840584A (en) | 2006-12-26 | 2008-10-16 | Gilead Sciences Inc | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
US20080194557A1 (en) * | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
EP2170887A2 (en) * | 2007-06-07 | 2010-04-07 | Amgen Inc. | Heterocyclic compounds as raf kinase modulators |
UY31137A1 (es) * | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
WO2009017822A2 (en) | 2007-08-02 | 2009-02-05 | Amgen Inc. | Pi3 kinase modulators and methods of use |
AU2008335772B2 (en) * | 2007-12-10 | 2014-11-27 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
US8198279B2 (en) | 2007-12-19 | 2012-06-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use |
PE20091268A1 (es) | 2007-12-19 | 2009-09-19 | Amgen Inc | Derivados heterociclicos como inhibidores de pi3 quinasa |
AR070317A1 (es) * | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
SG10201608813PA (en) | 2008-03-17 | 2016-12-29 | Ambit Biosciences Corp | Quinazoline derivatives as raf kinase modulators and methods of use thereof |
GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
CA2725014C (en) | 2008-05-30 | 2014-06-17 | Amgen Inc. | Inhibitors of pi3 kinase |
US8536187B2 (en) | 2008-07-03 | 2013-09-17 | Gilead Sciences, Inc. | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections |
JP5584215B2 (ja) * | 2008-09-02 | 2014-09-03 | ノバルティス アーゲー | ヘテロ環pimキナーゼ阻害剤 |
EP2348018A4 (en) | 2008-09-25 | 2012-04-25 | Kyorin Seiyaku Kk | HETEROCYCLIC BIARYLIC DERIVATIVE AND PDE INHIBITOR COMPRISING THE SAME AS ACTIVE INGREDIENT |
US20110224250A1 (en) * | 2008-10-09 | 2011-09-15 | Yasushi Kohno | Isoquinoline derivative, and pde inhibitor comprising same as active ingredient |
US8674095B2 (en) | 2008-12-19 | 2014-03-18 | Afraxis Holdings, Inc. | Compounds for treating neuropsychiatric conditions |
MX2011009796A (es) | 2009-03-20 | 2011-12-14 | Amgen Inc | Inhibidores de la cinasa pi3. |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
RS53494B9 (sr) | 2009-06-29 | 2020-11-30 | Incyte Holdings Corp | Pirimidinoni kao inhibitori pi3k |
US8372970B2 (en) | 2009-10-09 | 2013-02-12 | Afraxis, Inc. | 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders |
US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
PL2531502T3 (pl) | 2010-02-01 | 2014-08-29 | Cancer Research Tech Ltd | 1-(5-tert-Butylo-2-fenylo-2H-pirazol-3-ilo)-3-[2-fluoro-4-(1-metylo-2-okso-2,3-dihydro-1H-imidazo[4,5-b]pirydyn-7-yloksy)-fenylo]-mocznik i związki pokrewne oraz ich zastosowanie w terapii |
WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
WO2012087881A1 (en) | 2010-12-20 | 2012-06-28 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
WO2012149236A1 (en) * | 2011-04-28 | 2012-11-01 | Bristol-Myers Squibb Company | Novel bicyclic nitrogen containing heteroaryl tgr5 receptor modulators |
CN102850337B (zh) * | 2011-06-30 | 2015-01-07 | 四川大学 | 多氮唑联螺烯酮类化合物及其制备方法和用途 |
WO2013013614A1 (zh) * | 2011-07-28 | 2013-01-31 | 南京英派药业有限公司 | 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用 |
IL299533A (en) | 2011-09-02 | 2023-02-01 | Incyte Holdings Corp | Heterocycloamines as P13K inhibitors |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
UA109614C2 (uk) | 2011-12-30 | 2015-09-10 | ПОХІДНІ ТІЄНО[3,2-d]ПІРИМІДИНУ, ЩО МАЮТЬ ІНГІБУЮЧУ АКТИВНІСТЬ ВІДНОСНО ПРОТЕЇНКІНАЗ | |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
JP6013029B2 (ja) * | 2012-05-25 | 2016-10-25 | 千葉県 | 抗癌剤 |
CA2875372C (en) | 2012-06-15 | 2019-04-09 | Curegenix Inc. | Compound as wnt signaling inhibitor, composition, and use thereof |
WO2014052566A1 (en) * | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
CN105050598B (zh) * | 2012-09-28 | 2018-04-27 | 默沙东公司 | 作为erk抑制剂的新型化合物 |
TW201534597A (zh) | 2013-06-20 | 2015-09-16 | Ab Science | 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物 |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
CA2971872C (en) | 2014-12-22 | 2023-10-10 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Mutant idh1 inhibitors useful for treating cancer |
US9701677B2 (en) | 2014-12-24 | 2017-07-11 | Gilead Sciences, Inc. | Fused pyrimidine compounds |
MX2017008518A (es) | 2014-12-24 | 2017-10-25 | Gilead Sciences Inc | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). |
TWI699355B (zh) | 2014-12-24 | 2020-07-21 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
MA55193B1 (fr) | 2015-02-27 | 2022-10-31 | Incyte Holdings Corp | Procédés de préparation d'un inhibiteur de pi3k |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
WO2017207340A1 (de) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
US10294222B2 (en) * | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
WO2018060174A1 (de) | 2016-09-29 | 2018-04-05 | Bayer Pharma Aktiengesellschaft | Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln |
WO2018060072A1 (de) | 2016-09-29 | 2018-04-05 | Bayer Pharma Aktiengesellschaft | Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
EP3548007A4 (en) | 2016-12-01 | 2020-08-12 | Ignyta, Inc. | CANCER TREATMENT METHODS |
EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
ES2908602T3 (es) | 2017-07-29 | 2022-05-03 | Lutris Pharma Ltd | Nuevos inhibidores de BRaf y uso de los mismos para el tratamiento de reacciones cutáneas |
US10639313B2 (en) | 2017-09-01 | 2020-05-05 | Ndsu Research Foundation | Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation |
WO2019070742A1 (en) * | 2017-10-03 | 2019-04-11 | Sidecar Therapeutics, Inc. | APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITORS COMPOUNDS |
US11725185B2 (en) | 2017-12-28 | 2023-08-15 | University Of Houston System | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
US20210275516A1 (en) * | 2018-07-02 | 2021-09-09 | Ecole Polytechnique Federale De Lausanne (Epfl) | Lactate enhancing compounds and uses thereof |
EP3923911B1 (en) | 2019-02-12 | 2023-07-12 | Lutris Pharma Ltd. | Use of topical braf inhibitor compositions for treatment of radiation dermatitis |
CN110343070B (zh) * | 2019-08-14 | 2021-03-26 | 山东大学 | 一种微管蛋白抑制剂及其制备方法与应用 |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
EP4175719A1 (en) | 2020-07-02 | 2023-05-10 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
CN115322176B (zh) * | 2021-10-27 | 2024-04-16 | 温州医科大学 | 一种2,3-二氢苯并呋喃基取代的1h-吲唑类化合物及其制备和应用 |
TW202334089A (zh) | 2021-11-02 | 2023-09-01 | 美商夫雷爾醫療公司 | Pparg反向激動劑及其用途 |
CN114516870B (zh) * | 2022-02-10 | 2023-04-11 | 五邑大学 | 一种三唑并六元氮杂环-3-胺类化合物及其制备方法和应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618670A (en) | 1988-08-26 | 1997-04-08 | The United States Of America As Represented By The Department Of Health & Human Services | Detection method for c-raf-1 genes |
US5156841A (en) | 1988-08-26 | 1992-10-20 | United States Of America | Anti-tumor vaccine |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
DE19754774C2 (de) | 1997-11-28 | 1999-11-25 | Ulf R Rapp | Transgenes nicht-menschliches Säugetier mit einer onkogenen Mutante des Raf-1-Gens |
CN1149085C (zh) | 1997-12-22 | 2004-05-12 | 拜尔有限公司 | 用取代杂环脲抑制raf激酶 |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
DE60037597T2 (de) | 1999-11-22 | 2008-12-11 | Smithkline Beecham P.L.C., Brentford | Imidazol- Derivate |
WO2003016248A2 (en) | 2001-08-17 | 2003-02-27 | Bristol-Myers Squibb Company Patent Department | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace) |
CA2466762A1 (en) | 2001-12-04 | 2003-06-12 | Onyx Pharmaceuticals, Inc. | Raf-mek-erk pathway inhibitors to treat cancer |
US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
WO2004063190A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Fused heterocyclic derivates as ppar modulators |
MXPA05011536A (es) | 2003-04-30 | 2006-01-23 | Inst For Pharm Discovery Inc | Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b. |
PT1648874E (pt) * | 2003-07-30 | 2011-12-23 | Xenon Pharmaceuticals Inc | Derivados de piperazina e a sua utilização a título de agentes terapêuticos |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
US7390820B2 (en) | 2003-08-25 | 2008-06-24 | Amgen Inc. | Substituted quinolinone derivatives and methods of use |
US8362017B2 (en) | 2003-08-29 | 2013-01-29 | Exelixis, Inc. | C-kit modulators and methods of use |
AU2004281154A1 (en) | 2003-10-16 | 2005-04-28 | Novartis Vaccines And Diagnostics, Inc. | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer |
CA2537224A1 (en) | 2003-10-17 | 2005-05-06 | 4 Aza Bioscience Nv | Heterocycle-substituted pteridine derivatives and their use in therapy |
GB0326963D0 (en) | 2003-11-19 | 2003-12-24 | Glaxo Group Ltd | Compounds |
MXPA06012613A (es) * | 2004-05-07 | 2007-01-31 | Amgen Inc | Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer. |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
-
2006
- 2006-12-20 US US11/643,261 patent/US7989461B2/en not_active Expired - Fee Related
- 2006-12-21 AR ARP060105765A patent/AR057997A1/es unknown
- 2006-12-22 TW TW095148534A patent/TW200732339A/zh unknown
- 2006-12-22 CA CA2634769A patent/CA2634769C/en not_active Expired - Fee Related
- 2006-12-22 CA CA2753405A patent/CA2753405C/en not_active Expired - Fee Related
- 2006-12-22 ES ES06848110T patent/ES2392673T3/es active Active
- 2006-12-22 EP EP06848110A patent/EP1976836B9/en active Active
- 2006-12-22 EP EP12000993A patent/EP2481729A1/en not_active Withdrawn
- 2006-12-22 WO PCT/US2006/049187 patent/WO2007076092A2/en active Application Filing
- 2006-12-22 AU AU2006330888A patent/AU2006330888B2/en not_active Ceased
- 2006-12-26 PE PE2006001704A patent/PE20071328A1/es not_active Application Discontinuation
-
2011
- 2011-06-17 US US13/163,666 patent/US8440674B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2007076092A2 (en) | 2007-07-05 |
ES2392673T3 (es) | 2012-12-12 |
EP1976836B9 (en) | 2013-02-06 |
PE20071328A1 (es) | 2008-02-09 |
CA2753405A1 (en) | 2007-07-05 |
EP1976836A2 (en) | 2008-10-08 |
US20110251199A1 (en) | 2011-10-13 |
CA2753405C (en) | 2014-02-04 |
US7989461B2 (en) | 2011-08-02 |
AR057997A1 (es) | 2008-01-09 |
US8440674B2 (en) | 2013-05-14 |
AU2006330888B2 (en) | 2011-07-28 |
EP2481729A1 (en) | 2012-08-01 |
WO2007076092A3 (en) | 2007-11-15 |
EP1976836B1 (en) | 2012-08-22 |
CA2634769C (en) | 2011-12-13 |
US20070185324A1 (en) | 2007-08-09 |
CA2634769A1 (en) | 2007-07-05 |
AU2006330888A1 (en) | 2007-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200732339A (en) | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | |
WO2006039718A3 (en) | Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors | |
TW200635918A (en) | Pharmaceutical compounds | |
SE0104140D0 (sv) | Novel Compounds | |
MXPA05013349A (es) | Derivados de 2-amino-pirimidina como inhibidores de quinasa raf. | |
WO2006044823A3 (en) | Heteroaryl-substituted alkyne compounds and method of use | |
SE0202539D0 (sv) | Compounds | |
TW200610531A (en) | Phthalazine derivatives as PARP inhibitors | |
MXPA06009475A (es) | Derivados de quinazolina y usos terapeuticos de los mismos. | |
WO2008153947A3 (en) | Heterocyclic compounds as raf kinase modulators | |
TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
WO2009017822A3 (en) | Pi3 kinase modulators and methods of use | |
TW200621762A (en) | Novel compounds | |
TW200616978A (en) | Quinazolinone derivatives as parp inhibitors | |
TW200716606A (en) | Chemical compounds | |
TW200800963A (en) | Chemical compounds | |
HK1113352A1 (en) | Chemical compounds | |
SI1853588T1 (sl) | Kemične spojine | |
TW200744604A (en) | P38 MAP kinase inhibitors and methods for using the same | |
TW200517109A (en) | Substituted pyridinones | |
TW200612950A (en) | Quinazolinedione derivatives as PARP inhibitors | |
BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
GB0112348D0 (en) | Compounds | |
SE0300480D0 (sv) | Novel compounds | |
UA91002C2 (ru) | 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы |